OTC Markets OTCPK - Delayed Quote USD

Sanofi (SNYNF)

Compare
99.28
0.00
(0.00%)
At close: January 10 at 3:00:00 PM EST
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
48,856,000.00
46,444,000.00
45,389,000.00
39,175,000.00
37,369,000.00
Cost of Revenue
14,982,000.00
14,236,000.00
13,695,000.00
12,255,000.00
12,159,000.00
Gross Profit
33,874,000.00
32,208,000.00
31,694,000.00
26,920,000.00
25,210,000.00
Operating Expense
23,319,000.00
21,816,000.00
19,813,000.00
17,773,000.00
17,320,000.00
Operating Income
10,555,000.00
10,392,000.00
11,881,000.00
9,147,000.00
7,890,000.00
Net Non Operating Interest Income Expense
-817,000.00
-639,000.00
-288,000.00
-370,000.00
-335,000.00
Other Income Expense
-3,617,000.00
-2,600,000.00
-1,171,000.00
-979,000.00
6,223,000.00
Pretax Income
6,121,000.00
7,153,000.00
10,422,000.00
7,798,000.00
13,778,000.00
Tax Provision
1,509,000.00
1,602,000.00
2,006,000.00
1,558,000.00
1,807,000.00
Earnings from Equity Interest Net of Tax
-63,000.00
-115,000.00
68,000.00
39,000.00
359,000.00
Net Income Common Stockholders
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Diluted NI Available to Com Stockholders
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Basic EPS
3.60
4.31
6.69
4.97
9.81
Diluted EPS
3.59
4.30
6.66
4.95
9.76
Basic Average Shares
1,251,400.00
1,251,700.00
1,251,900.00
1,252,500.00
1,253,600.00
Diluted Average Shares
1,253,580.72
1,256,400.00
1,256,900.00
1,257,900.00
1,260,100.00
Total Operating Income as Reported
7,021,000.00
7,875,000.00
10,656,000.00
8,126,000.00
14,113,000.00
Total Expenses
38,301,000.00
36,052,000.00
33,508,000.00
30,028,000.00
29,479,000.00
Net Income from Continuing & Discontinued Operation
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Normalized Income
7,231,306.98
7,417,600.00
9,317,168.00
7,006,400.87
7,005,316.81
Interest Income
531,000.00
546,000.00
173,000.00
3,000.00
103,000.00
Interest Expense
822,000.00
659,000.00
461,000.00
389,000.00
434,000.00
Net Interest Income
-817,000.00
-639,000.00
-288,000.00
-370,000.00
-335,000.00
EBIT
6,943,000.00
7,812,000.00
10,883,000.00
8,187,000.00
14,212,000.00
EBITDA
9,058,000.00
12,604,000.00
14,303,000.00
11,538,000.00
17,883,000.00
Reconciled Cost of Revenue
14,982,000.00
11,616,000.00
12,328,000.00
10,484,000.00
10,169,000.00
Reconciled Depreciation
2,115,000.00
4,792,000.00
3,420,000.00
3,351,000.00
3,671,000.00
Net Income from Continuing Operation Net Minority Interest
4,506,000.00
5,400,000.00
8,371,000.00
6,223,000.00
12,294,000.00
Total Unusual Items Excluding Goodwill
-3,617,000.00
-2,600,000.00
-1,171,000.00
-979,000.00
6,087,000.00
Total Unusual Items
-3,617,000.00
-2,600,000.00
-1,171,000.00
-979,000.00
6,087,000.00
Normalized EBITDA
12,675,000.00
15,204,000.00
15,474,000.00
12,517,000.00
11,796,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-891,693.02
-582,400.00
-224,832.00
-195,599.13
798,316.81
12/31/2020 - 4/9/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RHHBF Roche Holding AG
301.37
0.00%
 
PFE.MX Pfizer Inc.
555.00
+0.91%
 
GLAXF GSK plc
16.86
0.00%
 
NONOF Novo Nordisk A/S
85.80
0.00%
 
NVS Novartis AG
99.08
-1.14%
 
BAYRY Bayer Aktiengesellschaft
5.12
+0.99%
 
GILD Gilead Sciences, Inc.
89.88
+0.83%
 
AZN AstraZeneca PLC
67.01
+0.65%
 
MRK Merck & Co., Inc.
99.25
-0.60%
 
BMY Bristol-Myers Squibb Company
55.83
-1.73%